A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder
Abstract
The efficacy and tolerability of Lu AA21004 in the prevention of relapse of major depressive disorder (MDD) in patients in remission after acute treatment was evaluated. Patients ( n=639) aged 18–75 years with a primary diagnosis of MDD with a current major depressive episode (MDE) ≥4 weeks’ duration, at least one prior MDE and a MADRS total score ≥26 received 12-week, open-label Lu AA21004 at 5 or 10mg/day. Patients in remission (MADRS ≤10) at both weeks 10 and 12 were assigned to double-blind treatment with either placebo or Lu AA21004 (fixed dose from Week 8).Patients (n=396) were treated, after random assignment to placebo (n=192) or Lu AA21004 (n=204). The primary analysis of time to relapse (full-analysis set, Cox proportional hazard model) showed a statistically significant difference in favour of Lu AA21004 versus placebo with a hazard ratio of 2.01 (95% confidence interval: 1.26–3.21; p=0.0035). The proportion of patients who relapsed was 13% in the Lu AA21004 group ( n=27) and 26% in the placebo group ( n=50). The withdrawal rates due to adverse events were 8% (open-label), and 3% (placebo) and 8% (Lu AA21004) (double-blind). Thus, Lu AA21004 was effective in preventing relapse of MDD and was well tolerated as maintenance treatment.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The relapse rates observed in the current study were similar to those reported in recently completed studies with desvenlafaxine versus placebo (13.6% vs. 28.3%) and vortioxetine versus placebo (13% vs. 26%).
“the relapse rates observed in the current study were similar to those reported in recently completed studies with desvenlafaxine versus placebo (13.6% vs. 28.3%; Rosenthal, Boyer, Vialet, Hwang, & Tourian, 2013) and vortioxetine versus placebo (13% vs. 26%; Boulenger, Loft, & Florea, 2012).”
From Relapse prevention with levomilnacipran ER in adults with major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study (2019) · cites this paper as Boulenger, Loft, & Florea, 2012
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · see citing works
Diagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Oxford University Press eBooks · doi:10.1037/10518-009 · Cited by 19,767 · see citing works
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · see citing works
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455 · see citing works
(1976) · Medical Entomology and Zoology · Cited by 8,899 · see citing works
Lecrubier, Y., Sheehan, D., Weiller, E., Amorim, P., Bonora, I., Sheehan, K. H., Janavs, J., & Dunbar, G. (1997) · European Psychiatry · doi:10.1016/s0924-9338(97)83296-8 · Cited by 3,513 · see citing works
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945 · cited 2× · see citing works
“When compared with the results of a meta-analysis based on seven clinical trials using a relapse-prevention design with placebo substitution after a one to two month open-label antidepressant treatment of MDD followed by a six-month relapse prevention period (Geddes et al., 2003), our results appear to be similar for…”
BackgroundResultBang-Andersen, B., Ruhland, T., Jørgensen, M., Smith, G., Frederiksen, K., Jensen, K. G., Zhong, H., Nielsen, S. M., Hogg, S., Mørk, A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101459g · Cited by 606 · see citing works
Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial
Rosenbaum, J. F., Fava, M., Hoog, S. L., Ascroft, R. C., & Krebs, W. B. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00126-7 · Cited by 574 · see citing works
Zimmerman, M., Mattia, J. I., & Posternak, M. A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.3.469 · Cited by 382 · see citing works
Alvarez, E., Perez, V., Dragheim, M., Loft, H., & Artigas, F. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001027 · Cited by 225 · see citing works
Self-citationBandelow, B., Baldwin, D. S., Dolberg, O. T., Andersen, H. F., & Stein, D. J. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0914 · Cited by 203 · see citing works
Baldwin, D. S., Loft, H., & Dragheim, M. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.11.008 · Cited by 158 · see citing works
Self-citationPrevention of relapse in generalized anxiety disorder by escitalopram treatment
Allgulander, C., Florea, I., & Huusom, A. K. T. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005973 · Cited by 130 · see citing works
Self-citationHollon, S. D., Shelton, R. C., Wisniewski, S., Warden, D., Biggs, M. M., Friedman, E. S., Husain, M., Kupfer, D. J., Nierenberg, A. A., Petersen, T. J., et al. (2006) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2005.07.008 · Cited by 120 · see citing works
Prediction of Recurrence in Recurrent Depression
ten Doesschate, M. C., Bockting, C., Koeter, M. W. J., Schene, A. H., & DELTA Study Group (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04858blu · Cited by 98 · see citing works
Sexual dysfunction associated with antidepressant drugs
Baldwin, D. S. (2004) · Expert Opinion on Drug Safety · doi:10.1517/14740338.3.5.457 · Cited by 84 · see citing works
Predictors of Relapse During Fluoxetine Continuation or Maintenance Treatment of Major Depression
McGrath, P. J., Stewart, J. W., Petkova, E., Quitkin, F. M., Amsterdam, J. D., Fawcett, J., Reimherr, F. W., Rosenbaum, J. F., & Beasley, C. M. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n0710 · Cited by 65 · see citing works
Relevance of Exclusion Criteria in Antidepressant Clinical Trials
Zetin, M., & Hoepner, C. T. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318058263f · Cited by 61 · see citing works
Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.
Adell, A. (2010) · PubMed · Cited by 34 · see citing works
Do Efficacy and Effectiveness Samples Differ in Antidepressant Treatment Outcome?
Seemüller, F., Möller, H., Obermeier, M., Adli, M., Bauer, M., Kronmüller, K., Holsboer, F., Brieger, P., Laux, G., Bender, W., et al. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05166blu · Cited by 21 · see citing works
Henigsberg, N., Mahableshwarkar, A. R., Jacobsen, P. L., Chen, Y., & Thase, M. E. (2011) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(11)70632-0 · Cited by 6 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,150 · see citing works
Malhi, G. S., Bassett, D., Boyce, P., Bryant, R., Fitzgerald, P. B., Fritz, K., Hopwood, M., Lyndon, B., Mulder, R., Murray, G., et al. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867415617657 · Cited by 842 · see citing works
A brief history of the development of antidepressant drugs: From monoamines to glutamate.
Hillhouse, T. M., & Porter, J. H. (2015) · Experimental and Clinical Psychopharmacology · doi:10.1037/a0038550 · Cited by 618 · see citing works
Sanchez, C., Asin, K. E., & Artigas, F. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.07.001 · Cited by 547 · see citing works
Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs
Dale, E., Bang‐Andersen, B., & Sánchez, C. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.03.011 · Cited by 238 · see citing works
Sim, K., Lau, W. K., Sim, J., Sum, M. Y., & Baldessarini, R. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv076 · Cited by 218 · see citing works
Bauer, M., Severus, E., Köhler, S., Whybrow, P. C., Angst, J., Möller, H.-J., & on behalf of the Wfsbp Task Force on Treatment Guidelines for Unipolar Depressive Disorders (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2014.1001786 · Cited by 199 · see citing works
Boulenger, J.-P., Loft, H., & Olsen, C. K. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000018 · Cited by 176 · see citing works
Self-citationPehrson, A. L., & Sanchez, C. (2014) · CNS Spectrums · doi:10.1017/s1092852913000540 · Cited by 161 · see citing works
Kato, M., Hori, H., Inoue, T., Iga, J., Iwata, M., Inagaki, T., Shinohara, K., Imai, H., Murata, A., Mishima, K., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0843-0 · Cited by 152 · see citing works
Montgomery, S. A., Nielsen, R. Z., Poulsen, L. H., & Häggström, L. (2014) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2424 · Cited by 143 · see citing works
“, 2012) and in relapse prevention (Boulenger et al., 2012).”
Citrome, L. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12350 · Cited by 140 · see citing works
The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants
Köhler, S., Cierpinsky, K., Kronenberg, G., & Adli, M. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115609072 · Cited by 137 · see citing works
Mahableshwarkar, A. R., Jacobsen, P. L., & Chen, Y. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.761600 · Cited by 135 · see citing works
Kishi, T., Ikuta, T., Sakuma, K., Okuya, M., Hatano, M., Matsuda, Y., & Iwata, N. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01824-z · Cited by 136 · see citing works
Jain, R., Mahableshwarkar, A. R., Jacobsen, P. L., Chen, Y., & Thase, M. E. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000727 · Cited by 132 · see citing works
The molecular pathophysiology of depression and the new therapeutics
Tian, H., Hu, Z., Xu, J., & Wang, C. (2022) · MedComm · doi:10.1002/mco2.156 · Cited by 122 · see citing works
Jacobsen, P. L., Mahableshwarkar, A. R., Chen, Y., Chrones, L., & Clayton, A. H. (2015) · The Journal of Sexual Medicine · doi:10.1111/jsm.12980 · Cited by 118 · see citing works
Vortioxetine (brintellix): a new serotonergic antidepressant.
(2015) · PubMed Central · Cited by 112 · see citing works
Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder
McIntyre, R. S., Florea, I., Tonnoir, B., Loft, H., Lam, R. W., & Christensen, M. C. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16m10744 · Cited by 100 · see citing works
Self-citationMahableshwarkar, A. R., Jacobsen, P. L., Chen, Y., Serenko, M., & Trivedi, M. H. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3839-0 · Cited by 98 · see citing works
Van Leeuwen, E., van Driel, M. L., Horowitz, M. A., Kendrick, T., Donald, M., De Sutter, A. I., Robertson, L., & Christiaens, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013495.pub2 · Cited by 90 · see citing works
Vortioxetine: a New Treatment for Major Depressive Disorder
Connolly, K. R., & Thase, M. E. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1133588 · Cited by 90 · see citing works
Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder
Alvarez, E., Artigas, F., & Perez, V. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s41387 · Cited by 84 · see citing works
Vieta, E., Sluth, L. B., & Olsen, C. K. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.11.053 · Cited by 72 · see citing works
Vortioxetine (Lu AA21004) in the long-term open-label treatment of major depressive disorder
Baldwin, D. S., Hansen, T. F., & Florea, I. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.725035 · Cited by 71 · see citing works
Self-citationPae, C., Wang, S., Han, C., Lee, S.-J., Patkar, A. A., Masand, P. S., & Serretti, A. (2015) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.140120 · Cited by 71 · see citing works
Vortioxetine for depression in adults
Koesters, M., Ostuzzi, G., Guaiana, G., Breilmann, J., & Barbui, C. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011520.pub2 · Cited by 67 · see citing works
Leiser, S. C., Pehrson, A. L., Robichaud, P. J., & Sánchez, C. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12782 · Cited by 63 · see citing works
Vortioxetine: First Global Approval
Gibb, A. D., & Deeks, E. D. (2013) · Drugs · doi:10.1007/s40265-013-0161-9 · Cited by 64 · see citing works
Al-Sukhni, M., Maruschak, N. A., & McIntyre, R. S. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1046836 · Cited by 58 · see citing works
New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder
Katona, C., & Katona, C. (2014) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s39544 · Cited by 56 · see citing works
A Review of Novel Antidepressants: A Guide for Clinicians
Faquih, A. E., Memon, R. I., Hafeez, H., Zeshan, M., & Naveed, S. (2019) · Cureus · doi:10.7759/cureus.4185 · Cited by 54 · see citing works
Mahableshwarkar, A. R., Jacobsen, P. L., Chen, Y., & Simon, J. S. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12328 · Cited by 50 · see citing works
Deardorff, W. J., & Grossberg, G. T. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.960842 · Cited by 49 · see citing works
Vortioxetine: A Review of Its Use in Major Depressive Disorder
Garnock-Jones, K. P. (2014) · CNS Drugs · doi:10.1007/s40263-014-0195-x · Cited by 48 · see citing works
Nishimura, A., Aritomi, Y., Sasai, K., Kitagawa, T., & Mahableshwarkar, A. R. (2018) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12565 · Cited by 45 · see citing works
Mahableshwarkar, A. R., Jacobsen, P. L., Serenko, M., & Chen, Y. (2014) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2371 · Cited by 44 · see citing works
Jacobsen, P. L., Zhong, W., Nomikos, G. G., & Clayton, A. H. (2019) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2019.06.018 · Cited by 43 · see citing works
A Review of Antidepressant Therapy in Primary Care
Kennedy, S. H. (2013) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.12r01420 · Cited by 40 · see citing works
Vortioxetina: una nueva alternativa en el trastorno depresivo mayor
Salagre, E., Grande, I., Solé, B., Sánchez‐Moreno, J., & Vieta, E. (2017) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2017.06.006 · Cited by 40 · see citing works
The US Food and Drug Administration’s Perspective on the New Antidepressant Vortioxetine
Zhang, J., Mathis, M. V., Sellers, J. W., Kordzakhia, G., Jackson, A. J., Dow, A. L., Yang, P., Fossom, L. H., Zhu, H., Patel, H., et al. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14r09164 · Cited by 38 · see citing works
Schatzberg, A. F., Blier, P., Culpepper, L., Jain, R., Papakostas, G. I., & Thase, M. E. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14027ah1 · Cited by 35 · see citing works
Under the Influence: The Interplay among Industry, Publishing, and Drug Regulation
Cosgrove, L., Vannoy, S. D., Mintzes, B. J., & Shaughnessy, A. F. (2016) · Accountability in Research · doi:10.1080/08989621.2016.1153971 · Cited by 31 · see citing works
Bobo, W. V., Kelliny, M., Croarkin, P. E., & Moore, K. M. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s55313 · Cited by 32 · see citing works
Effectiveness of long-term vortioxetine treatment of patients with major depressive disorder
Vieta, E., Loft, H., & Florea, I. (2017) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2017.06.012 · Cited by 30 · see citing works
Self-citationLlorca, P., Lançon, C., Brignone, M., Rive, B., Salah, S., Ereshefsky, L., & François, C. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.969566 · Cited by 29 · see citing works
Vortioxetine: A new alternative for the treatment of major depressive disorder
Salagre, E., Grande, I., Solé, B., Sánchez‐Moreno, J., & Vieta, E. (2018) · Revista de Psiquiatría y Salud Mental (English Edition) · doi:10.1016/j.rpsmen.2018.02.005 · Cited by 28 · see citing works
Cognitive dysfunctions in depression – underestimated symptom or new dimension?
Jarema, M., Dudek, D., & Czernikiewicz, A. (2014) · Psychiatria Polska · doi:10.12740/pp/31215 · Cited by 29 · see citing works
Christensen, M. C., Florea, I., Loft, H., & McIntyre, R. S. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.11.074 · Cited by 26 · see citing works
Self-citationVortioxetine for the Treatment of Depression
Pearce, E. F., & Murphy, J. A. (2014) · Annals of Pharmacotherapy · doi:10.1177/1060028014528305 · Cited by 26 · see citing works
Citrome, L., DiBernardo, A., & Singh, J. B. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.106 · Cited by 26 · see citing works
Orsolini, L., Tomasetti, C., Valchera, A., Iasevoli, F., Buonaguro, E. F., Vellante, F., Fornaro, M., Fiengo, A. L. C., Mazza, M., Vecchiotti, R., et al. (2016) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2016.1173545 · Cited by 25 · see citing works
Fu, J., & Chen, Y. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3633-z · Cited by 23 · see citing works
McIntyre, R. S. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s150589 · Cited by 23 · see citing works
Subeesh, V., Singh, H., Maheswari, E., & Beulah, E. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.09.005 · Cited by 21 · see citing works
Vortioxetine for the treatment of major depressive disorder
Tritschler, L., Felice, D., Colle, R., Guilloux, J., Corruble, E., Gardier, A. M., & David, D. J. P. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.950655 · Cited by 21 · see citing works
Soini, E. J., Hallinen, T., Brignone, M., Campbell, R., Diamand, F., Cure, S., Aalto-Setälä, M., Danchenko, N., Koponen, H., & Kolasa, K. (2016) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2017.1240617 · Cited by 20 · see citing works
Baldessarini, R. J., Lau, W. K., Sim, J. Z. T., Sum, M. Y., & Sim, K. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw092 · Cited by 19 · see citing works
Mattingly, G. W., Necking, O., Schmidt, S. N., Reines, E. H., & Ren, H. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2178082 · Cited by 19 · see citing works
Thase, M. E., Jacobsen, P. L., Hanson, E., Xu, R., Tolkoff, M., & Murthy, N. V. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.02.002 · Cited by 17 · see citing works
Zhou, D., Lv, Z., Shi, L., Zhou, X., Lin, Q., Chen, X., Wan, L.-Y., Li, Y., Ran, L., Huang, Y., et al. (2020) · Psychological Medicine · doi:10.1017/s0033291720001610 · Cited by 13 · see citing works
Pharmacokinetic evaluation of vortioxetine for the treatment of major depressive disorder
Dubovsky, S. L. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.904286 · Cited by 14 · see citing works
Naik, H., Chan, S., Vakilynejad, M., Chen, G., Loft, H., Mahableshwarkar, A. R., & Areberg, J. (2015) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12513 · Cited by 13 · see citing works
Self-citationDepression and Cerebrovascular Disease: Could Vortioxetine Represent a Valid Treatment Option?
Carta, M. G., Pala, A. N., Finco, G., Musu, M., & Moro, M. F. (2015) · Clinical Practice and Epidemiology in Mental Health · doi:10.2174/1745017901511010144 · Cited by 12 · see citing works
Effects of sertraline, duloxetine, vortioxetine, and idazoxan in the rat affective bias test
Refsgaard, L. K., Haubro, K., Pickering, D. S., Stuart, S. A., Robinson, E. S. J., & Andreasen, J. T. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4407-6 · Cited by 12 · see citing works
Durgam, S., Chen, C., Migliore, R., Prakash, C., & Thase, M. E. (2019) · Depression and Anxiety · doi:10.1002/da.22872 · Cited by 11 · see citing works
Lachaîne, J., Beauchemin, C., Bibeau, J., Patenaude, J., Chokka, P. R., Proulx, J., & Bougie, J. K. (2019) · CNS Spectrums · doi:10.1017/s1092852919000853 · Cited by 11 · see citing works
On assessing potential efficacy for vortioxetine in generalized anxiety disorder
Baldwin, D. S., & Nutt, D. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.07.018 · Cited by 10 · see citing works
Vortioxetine: a review of new antidepressant
Mohr, P., Melicher, T., & Knytl, P. (2016) · Psychiatrie pro praxi · doi:10.36290/psy.2016.009 · Cited by 9 · see citing works
Elhenawee, M., Saleh, H., Hussien, E. M., & Derar, A. R. (2020) · IEEE Sensors Journal · doi:10.1109/jsen.2020.2997738 · Cited by 9 · see citing works
Vortioxetine in the treatment of major depressive disorder
Baldwin, D. S., & Hanumanthaiah, V. B. (2015) · Future Neurology · doi:10.2217/fnl.14.69 · Cited by 9 · see citing works
Mehra, A., Khanna, J., Singh, G., Sachdeva, V., & Bedi, N. (2025) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-025-00308-y · Cited by 8 · see citing works
Montano, C. B., Jackson, W. C., Vanacore, D., & Weisler, R. H. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s337703 · Cited by 8 · see citing works
Zaccoletti, D., Mosconi, C., Gastaldon, C., Benedetti, L., Gottardi, C., Papola, D., Ponzi, O., Purgato, M., Naudet, F., Cristea, I. A., et al. (2025) · The Lancet Psychiatry · doi:10.1016/s2215-0366(25)00330-x · Cited by 10 · see citing works
Bose, R., Hamdani, S. U., Minhas, F. A., & Herr, K. J. (2022) · Current Medical Research and Opinion · doi:10.1080/03007995.2022.2031146 · Cited by 7 · see citing works
Arıkan, M. K., İlhan, R., Pogarell, O. M., & Metin, B. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.01.024 · Cited by 6 · see citing works
Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial
Mills, N. T., Sampson, E., Fourrier, C., & Baune, B. T. (2020) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa092 · Cited by 6 · see citing works
Overview of approved psychiatric medications 2008-2023: A systematic review
IsHak, W. W., Totlani, J., Murphy, N., Renteria, S., Chang, T. Y., Abdelsalam, R., Salem, M., Meyer, A., Khan, R., Chandy, T., et al. (2024) · World Journal of Advanced Research and Reviews · doi:10.30574/wjarr.2024.21.3.0705 · Cited by 5 · see citing works
François, C., Nielsen, R. Z., Danchenko, N., Williams, V. S. L., & Lançon, C. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1299701 · Cited by 5 · see citing works
Systematic review of gender bias in vortioxetine clinical trials
Santos-Casado, M., Guisado-Gil, A. B., & Santos‐Ramos, B. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110088 · Cited by 5 · see citing works
Gao, S., Xie, X., Fan, L., & Zhang, D. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.12214 · Cited by 4 · see citing works
Weiss, F., Pacciardi, B., D’Alessandro, G., Caruso, V., Maremmani, I., Pini, S., & Perugi, G. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020531 · Cited by 4 · see citing works
Adair, M., Bose, R., & Schmidt, S. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2382773 · Cited by 3 · see citing works
La vortioxétine : un nouvel antidépresseur pour traiter les épisodes dépressifs caractérisés
Colle, R., & Corruble, E. (2015) · L Encéphale · doi:10.1016/j.encep.2015.07.007 · Cited by 4 · see citing works
Levomilnacipran and vortioxetine: Review of new pharmacotherapies for major depressive disorder
Liu, M. T. (2015) · World Journal of Pharmacology · doi:10.5497/wjp.v4.i1.17 · Cited by 4 · see citing works
Effective Vortioxetine Dose Varies with Extent of Antidepressant Use Across Countries
Tegin, C., Tegin, G., & El‐Mallakh, R. S. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4559 · Cited by 4 · see citing works
Bai, W., Song, H., Hu, Y., Zhang, X., Wang, X., Guo, C., Qiu, B., & Dong, Z. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s428771 · Cited by 3 · see citing works
Barbosa, E. C., da Silva, G. H. S., Sbardelotto, Â. E. E., Barroso, D. C., de Lima, F. R., Paez, L. E. F. E., Lança, S. B., Petrucci, A. B. C., Guimarães, F. B. D. M., & Nascimento, A. L. (2024) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2024.104222 · Cited by 3 · see citing works
Roman, M. W., & Wilkinson, S. M. (2014) · Issues in Mental Health Nursing · doi:10.3109/01612840.2014.955155 · Cited by 3 · see citing works
Jacobsen, P. L., Zhong, W., Xu, R., & Nomikos, G. G. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.01.090 · Cited by 3 · see citing works
Minhas, F. A., Rana, R. Z., Hamdani, S. U., & Rana, M. H. (2021) · Journal of Pakistan Psychiatric Society · doi:10.63050/jpps.18.01.87 · Cited by 3 · see citing works
Psychopharmakotherapie – klinisch-empirische Grundlagen
Volz, H., Kasper, S. F., & Möller, H. (2017) · Springer eBooks · doi:10.1007/978-3-662-49295-6_31 · Cited by 3 · see citing works
Donepezil and α‐synuclein Constipation: A 60 Month Follow-Up
Lepkowsky, C. M. (2022) · POJ Clinical Case Reports · doi:10.32648/2639-3298/4/1/1 · Cited by 2 · see citing works
Cuomo, A., Barillà, G., Cattolico, M., Pardossi, S., Mariantoni, E., Koukouna, D., Carmellini, P., & Fagiolini, A. M. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2333394 · Cited by 2 · see citing works
Deardorff, W. J., & Grossberg, G. T. (2015) · Current Geriatrics Reports · doi:10.1007/s13670-015-0140-y · Cited by 2 · see citing works
Review of a New Multimodal Antidepressant Vortioxetine
Oppa, M., Cesnekova, D., Nosalova, G., & Ondrejka, I. (2016) · Acta Medica Martiniana · doi:10.1515/acm-2016-0011 · Cited by 3 · see citing works
Vortioxetine: a comprehensive update on a new-generation antidepressant
Evren, C. (2021) · Dusunen Adam The Journal of Psychiatry and Neurological Sciences · doi:10.14744/dajpns.2021.00115 · Cited by 2 · see citing works
Ng, C. G., Abousheishaa, A. A., Low, S.-Y., Zainal, N. Z., Thong, K. S., Awaluddin, A., Loo, T. H., Yacob, S., Jaafar, N. R. N., Taib, N. I. A., et al. (2023) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2023.24.8.2583 · Cited by 2 · see citing works
Donepezil and α-synuclein Constipation: A 36 Month Follow-Up
Lepkowsky, C. M. (2019) · POJ Clinical Case Reports · doi:10.32648/2639-3298/2/1/002 · Cited by 2 · see citing works
- Authors
- Boulenger, J.-P., Loft, H., & Florea, I.
- Affiliations
- Université Montpellier 1 (FR)
- Lundbeck (Denmark) (DK)
- ORCID
- Florea, Ioana
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2012-04-09
- Volume
- 26
- Issue
- 11
- Pages
- 1408-1416
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2066283885
- Semantic Scholar
- 09b9fc5799e896bbdda5703b74a14db0438fa09a
- Cited by
- 127
- References
- 22
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 7 · 2023: 5 · 2022: 7 · 2021: 5 · 2020: 7 · 2019: 7 · 2018: 2 · 2017: 10 · 2016: 12 · 2015: 25 · 2014: 18 · 2013: 7 · 2012: 5
- FWCI
- 12.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- H. Lundbeck A/S
- Topics
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Social Sciences › Psychology › Social Psychology › Mental Health Treatment and Access
- Keywords
- vortioxetine, major depressive disorder, relapse prevention, maintenance therapy, antidepressant efficacy, drug tolerability, time to relapse, remission, adverse events
- MeSH terms
- Vortioxetine, Adolescent, Adult, Aged, Antidepressive Agents, Major Depressive Disorder, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Piperazines, Sulfides, Proportional Hazards Models, Treatment Outcome, Secondary Prevention, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
